Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 5/2013

01-05-2013 | Original paper

Do diagnostic and treatment delays for colorectal cancer increase risk of death?

Authors: Sandi L. Pruitt, Amy Jo Harzke, Nicholas O. Davidson, Mario Schootman

Published in: Cancer Causes & Control | Issue 5/2013

Login to get access

Abstract

Background

Using 1998–2005 SEER-Medicare data, we examined the effect of diagnostic and treatment delays on all-cause and colorectal cancer (CRC)-specific death among US adults aged ≥ 66 years with invasive colon or rectal cancer. We hypothesized that longer delays would be associated with a greater risk of death.

Methods

We defined diagnostic and treatment delays, respectively, as days between (1) initial medical consult for CRC symptoms and pathologically confirmed diagnosis (maximum: 365 days) and (2) pathologically confirmed diagnosis and treatment (maximum: 120 days). Cases (CRC deaths) and controls (deaths due to other causes or censored) were matched on survival time. Logistic regression analyses adjusted for sociodemographic, tumor, and treatment factors.

Results

Median diagnostic delays were 60 (colon) and 40 (rectal) days and treatment delays were 13 (colon) and 16 (rectal) days in 10,663 patients. Colon cancer patients with the longest diagnostic delays (8–12 months vs. 14–59 days) had higher odds of all-cause (aOR: 1.31 CI: 1.08–1.58), but not CRC-specific death. Colon cancer patients with the shortest treatment delays (<1 vs. 1–2 weeks) had higher odds of all-cause (aOR: 1.23 CI: 1.01–1.49), but not CRC-specific death. Among rectal cancer patients, delays were not associated with risk of all-cause or CRC-specific death.

Conclusions

Longer delays of up to 1 year after symptom onset and 120 days for treatment did not increase odds of CRC-specific death. There may be little clinical benefit in detecting and treating existing symptomatic disease earlier. Screening prior to symptom onset must remain the primary goal to reduce CRC incidence, morbidity, and mortality.
Appendix
Available only for authorised users
Literature
1.
2.
Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328(19):1365–1371PubMedCrossRef
3.
Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS (1992) A case–control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 326(10):653–657PubMedCrossRef
4.
Centers for Disease Control and Prevention (CDC) (2011) Vital signs: colorectal cancer screening, incidence, and mortality—United States, 2002–2010. MMWR Morb Mortal Wkly Rep 60(26):884–889
5.
6.
Ramos M, Esteva M, Cabeza E, Campillo C, Llobera J, Aguilo A (2007) Relationship of diagnostic and therapeutic delay with survival in colorectal cancer: a review. Eur J Cancer 43(17):2467–2478PubMedCrossRef
7.
Ramos M, Esteva M, Cabeza E, Llobera J, Ruiz A (2008) Lack of association between diagnostic and therapeutic delay and stage of colorectal cancer. Eur J Cancer 44(4):510–521PubMedCrossRef
8.
Terhaar sive Droste JS, Oort FA, van der Hulst RW, Coupe VM, Craanen ME, Meijer GA, Morsink LM, Visser O, van Wanrooij RL, Mulder CJ (2010) Does delay in diagnosing colorectal cancer in symptomatic patients affect tumor stage and survival? A population-based observational study. BMC Cancer 10:332
9.
Fisher DA, Zullig LL, Grambow SC, Abbott DH, Sandler RS, Fletcher RH, El-Serag HB, Provenzale D (2010) Determinants of medical system delay in the diagnosis of colorectal cancer within the Veteran Affairs Health System. Dig Dis Sci 55(5):1434–1441PubMedCrossRef
10.
Torring ML, Frydenberg M, Hamilton W, Hansen RP, Lautrup MD, Vedsted P (2012) Diagnostic interval and mortality in colorectal cancer: U-shaped association demonstrated for three different datasets. J Clin Epidemiol 65(6):669–678PubMedCrossRef
11.
Torring ML, Frydenberg M, Hansen RP, Olesen F, Hamilton W, Vedsted P (2011) Time to diagnosis and mortality in colorectal cancer: a cohort study in primary care. Br J Cancer 104(6):934–940PubMedCrossRef
12.
13.
Jullumstro E, Lydersen S, Moller B, Dahl O, Edna TH (2009) Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer. Eur J Cancer 45(13):2383–2390PubMedCrossRef
14.
Simunovic M, Rempel E, Theriault ME, Baxter NN, Virnig BA, Meropol NJ, Levine MN (2009) Influence of delays to nonemergent colon cancer surgery on operative mortality, disease-specific survival and overall survival. Can J Surg 52(4):E79–E86PubMed
15.
Wattacheril J, Kramer JR, Richardson P, Havemann BD, Green LK, Le A, El-Serag HB (2008) Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival. Aliment Pharmacol Ther 28(9):1166–1174PubMedCrossRef
16.
Bilimoria KY, Ko CY, Tomlinson JS, Stewart AK, Talamonti MS, Hynes DL, Winchester DP, Bentrem DJ (2011) Wait times for cancer surgery in the United States: trends and predictors of delays. Ann Surg 253(4):779–785PubMedCrossRef
17.
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8):IV-3-18
18.
Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BKe (eds)SEER cancer statistics review, 1975–2007, National Cancer Institute. Bethesda, MD. http://​seer.​cancer.​gov/​csr/​1975_​2007/​, based on November 2009 SEER data submission, posted to the SEER web site, 2010
19.
Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ (2008) Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol 26(23):3860–3866PubMedCrossRef
20.
21.
Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD (1999) The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer 79(5–6):858–864PubMedCrossRef
22.
Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ (1999) Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 353(9159):1119–1126PubMedCrossRef
23.
Porter MP (2010) Examining the association between delay in diagnosis and decreased survival in bladder cancer. Cancer 116(22):5122–5125PubMedCrossRef
24.
25.
Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16(3):241–249PubMedCrossRef
26.
27.
Jung SY, Sereika SM, Linkov F, Brufsky A, Weissfeld JL, Rosenzweig M (2011) The effect of delays in treatment for breast cancer metastasis on survival. Breast Cancer Res Treat 130(3):953–964PubMedCrossRef
28.
Hu C, Xing Y, Cormier JN, Chang GJ (2009) The validity of cause of death coding within the Surveillance, Epidemiology, and End Results (SEER) Registry. J Clin Oncol 27(15s):6544
29.
Lund JL, Harlan LC, Yabroff KR, Warren JL (2010) Should cause of death from the death certificate be used to examine cancer-specific survival? A study of patients with distant stage disease. Cancer Invest 28(7):758–764PubMedCrossRef
30.
Maguire A, Porta M, Malats N, Gallen M, Pinol JL, Fernandez E (1994) Cancer survival and the duration of symptoms. An analysis of possible forms of the risk function. ISDS II Project Investigators. Eur J Cancer 30A(6):785–792PubMedCrossRef
31.
32.
Ford AC, Veldhuyzen van Zanten SJ, Rodgers CC, Talley NJ, Vakil NB, Moayyedi P (2008) Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. Gut 57(11):1545–1553PubMedCrossRef
33.
Jellema P, van der Windt DA, Bruinvels DJ, Mallen CD, van Weyenberg SJ, Mulder CJ, de Vet HC Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. BMJ 340:c1269
34.
El-Serag HB, Petersen L, Hampel H, Richardson P, Cooper G (2006) The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs. Arch Intern Med 166(20):2202–2208PubMedCrossRef
35.
Fisher DA, Grubber JM, Castor JM Coffman CJ (2010) Ascertainment of colonoscopy indication using administrative data. Dig Dis Sci 55(6):1721–1725
36.
American Medical Association (2001) Physicians’ current procedural terminology CPT 2002. American Medical Association, Chicago
37.
Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML (2008) Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100(12):888–897PubMedCrossRef
38.
Hodgson DC, Fuchs CS, Ayanian JZ (2001) Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 93(7):501–515PubMedCrossRef
39.
Polite BN, Dignam JJ, Olopade OI (2006) Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 24(14):2179–2187PubMedCrossRef
40.
Schenck AP, Klabunde CN, Warren JL, Peacock S, Davis WW, Hawley ST, Pignone M, Ransohoff DF (2007) Data sources for measuring colorectal endoscopy use among Medicare enrollees. Cancer Epidemiol Biomarkers Prev 16(10):2118–2127PubMedCrossRef
41.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef
42.
43.
Parchman ML, Culler SD (1999) Preventable hospitalizations in primary care shortage areas. An analysis of vulnerable Medicare beneficiaries. Arch Fam Med 8(6):487–491PubMedCrossRef
44.
45.
46.
47.
Patwardhan MB, Samsa GP, McCrory DC, Fisher DA, Mantyh CR, Morse MA, Prosnitz RG, Cline KE, Gray RN (2006) Cancer care quality measures: diagnosis and treatment of colorectal cancer. Evidence report/technology assessment no. 138. (Prepared by the Duke Evidence based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 06-E002. Agency for Healthcare Research and Quality, Rockville, MD
48.
49.
50.
Korsgaard M, Pedersen L, Sorensen HT, Laurberg S (2006) Reported symptoms, diagnostic delay and stage of colorectal cancer: a population-based study in Denmark. Colorectal Dis 8(8):688–695PubMedCrossRef
51.
Singh H, De Coster C, Shu E, Fradette K, Latosinsky S, Pitz M, Cheang M, Turner D (2010) Wait times from presentation to treatment for colorectal cancer: a population-based study. Can J Gastroenterol 24 (1):33–39
52.
Allgar VL, Neal RD (2005) Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS Patients: cancer. Br J Cancer 92(11):1959–1970PubMedCrossRef
53.
Winawer SJ, Fletcher RH, Miller L, Godlee F, Stolar MH, Mulrow CD, Woolf SH, Glick SN, Ganiats TG, Bond JH, Rosen L, Zapka JG, Olsen SJ, Giardiello FM, Sisk JE, Van Antwerp R, Brown-Davis C, Marciniak DA, Mayer RJ (1997) Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 112(2):594–642PubMedCrossRef
54.
Markowitz SD, Bertagnolli MM (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 361(25):2449–2460PubMedCrossRef
55.
Porta M, Fernandez E, Alguacil J (2003) Semiology, proteomics, and the early detection of symptomatic cancer. J Clin Epidemiol 56(9):815–819PubMedCrossRef
56.
Singh H, Daci K, Petersen LA, Collins C, Petersen NJ, Shethia A, El-Serag HB (2009) Missed opportunities to initiate endoscopic evaluation for colorectal cancer diagnosis. Am J Gastroenterol 104(10):2543–2554PubMedCrossRef
57.
McConnell YJ, Inglis K, Porter GA (2010) Timely access and quality of care in colorectal cancer: are they related? Int J Qual Health Care 22(3):219–228PubMedCrossRef
58.
Rai S, Kelly MJ (2007) Prioritization of colorectal referrals: a review of the 2-week wait referral system. Colorectal Dis 9(3):195–202PubMedCrossRef
59.
Siminoff LA, Rogers HL, Thomson MD, Dumenci L, Harris-Haywood S (2011) Doctor, what’s wrong with me? Factors that delay the diagnosis of colorectal cancer. Patient Educ Couns 84(3):352–358PubMedCrossRef
60.
Hu CY, Delclos GL, Chan W, Du XL (2010) Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Med Oncol 28(4):1062–1074
Metadata
Title
Do diagnostic and treatment delays for colorectal cancer increase risk of death?
Authors
Sandi L. Pruitt
Amy Jo Harzke
Nicholas O. Davidson
Mario Schootman
Publication date
01-05-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 5/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0172-6

Other articles of this Issue 5/2013

Cancer Causes & Control 5/2013 Go to the issue

Original paper

Quantitative exposure metrics for sleep disturbance and their association with breast cancer risk

Original paper

Anthropometric factors in relation to risk of glioma

Original paper

Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status

Original paper

Social support and cancer incidence and mortality: the JPHC study cohort II

Original paper

Dietary intake of vegetables, folate, and antioxidants and the risk of Barrett’s esophagus

Original paper

Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits